Hydroquinone

The selected 4% cream manufacturer describes gradual lightening of melasma/chloasma, freckles, lentigines, and other melanin hyperpigmentation. This is a summary of its published manufacturer label, not a claim that FDA reviewed and approved these indications. Evaluate the lesion and diagnosis before treating; general whole-body cosmetic lightening is not the supplied regimen.

Selected Nivagen cream is listed UNAPPROVED DRUG OTHER, with no Orange Book equivalence claim. FDA identifies Tri-Luma as the only FDA-approved hydroquinone-containing drug; that steroid/retinoid combination’s approval does not transfer to plain 4% cream. Hydroquinone skin-lightening products are not approved for OTC sale. Treat prescription listing, individual approval, and therapeutic equivalence as distinct questions.

Apply the selected 4% cream to affected areas and rub in twice daily, morning and bedtime, or as directed. Limit treatment to relatively small areas. Discontinue if there is no improvement after 2 months. No approved whole-body dose, gram maximum, long-term cycling schedule, or combination-to-single-drug substitution is established by this label.

Before use, apply a small amount to unbroken skin and assess at 24 hours. Minor redness alone does not preclude treatment; itching, vesicles, or excessive inflammation means further treatment is not advised. The product contains no sunscreen: label calls for broad-spectrum SPF 15 or greater or protective clothing and avoidance of unnecessary sun. This minimum label statement is not a claim that every skin/UV setting is adequately protected at that SPF.

The contraindications text says pregnancy and ages 12 and under safety are unestablished, whereas pediatric-use/dose text says below 12. At exactly 12, seek clinician clarification; no pediatric dose or inferred minimum approved age is supplied. Renal/hepatic impairment has no quantitative schedule in this label.

Prior sensitivity/allergy to hydroquinone or any product ingredient is contraindicated. The same section notes unestablished safety in pregnancy and children 12 and under; pregnancy text separately permits use only if clearly needed. Those evidence-limit statements are not silently recast as FDA-approved absolute pregnancy/pediatric contraindications. The conflicting exact age 12 wording requires prescriber review.

The selected published manufacturer label has no boxed warning. It remains an unapproved product with clinically important allergy, irritation, and ochronosis risks; no-box status is not regulatory validation.

Reported local reactions include dryness/fissuring, redness, stinging, and contact dermatitis; discontinue for hypersensitivity. FDA reports serious reactions including facial swelling and potentially permanent ochronosis. Accidental ingestion needs immediate medical/poison-center assessment. The manufacturer’s limited systemic-overdose reporting is not a home-treatment algorithm or proof that swallowing the cream is safe.

The label cautions about medicines known to cause photosensitivity. Review those exposures and the sun-protection plan before treatment; it supplies no drug-specific dose-adjustment or spacing rule.

A clinician should review the exact topical regimen rather than assume a different concentration or combination product is interchangeable. Nivagen’s label expressly disclaims FDA therapeutic/bioequivalence testing. It does not supply a validated interaction matrix for retinoids, corticosteroids, peels, or bleaching agents, so no universal combination instructions are invented.

Manufacturer labeling retains categoryC language, no topical reproduction studies, and use only if clearly needed. Human milk excretion is unknown and nursing caution is advised. No fetal-risk percentage, infant exposure limit, or proven safe pregnancy/breastfeeding regimen is established here.

Children’s safety/effectiveness is unestablished with inconsistent exact 12-year boundary wording as described above. The label gives no separate geriatric study-based dose; individual diagnosis, local tolerance, and supervision remain important. No pediatric cosmetic-lightening regimen is supplied.

The selected label provides no validated renal/hepatic PK or dose-adjustment schedule. That missing evidence is not proof of unrestricted use in severe disease. Limit treatment to prescribed affected areas and obtain individualized review; no systemic-drug algorithm is transplanted into this cream.

Manufacturer labeling describes reversible depigmentation through inhibition of tyrosine oxidation toward dopa and other melanocyte processes. Sun/UV exposure can restore pigmentation, which supports its photoprotection instructions. No permanent-cure or selective lesion-only molecular effect is claimed.

FDA notes skin absorption of hydroquinone. This plain 4% product label provides no measured product-specific systemic bioavailability, plasma half-life, clearance, or organ-impairment PK study. Do not borrow Tri-Luma combination exposure data or interpret the lack of an overdose series as proof of no absorption.

Check diagnosis, small-area sensitivity-test response, local irritation/allergy, unwanted depigmentation, ochronosis, sun exposure, and response by 2 months. The label recommends close supervision but supplies no universal laboratory interval or established long-term maintenance algorithm.

Apply only as directed, avoid eyes/mucous membranes, and use the prescribed photoprotection plan. Stop and contact the clinician for itching/vesicles, marked inflammation, allergy, or blue-black darkening. Lack of benefit at 2 months requires discontinuation/review. Keep away from children and obtain immediate help after swallowing; do not purchase unapproved OTC hydroquinone for self-directed lightening.

Nivagen hydroquinone USP4% cream is supplied in 28.4 g tube, NDC 75834-137-01. No verified color/imprint identification is invented. It is not represented as an Orange Book equivalent or a currently approved Tri-Luma substitute.

Covered topical cream contains hydroquinone 40 mg/g (4%). Lower/higher strengths, compounded preparations, OTC skin-lightening products, and fluocinolone/hydroquinone/tretinoin combination have separate status and instructions; no oral or ophthalmic use is supported.

Store at 20–25°C. Manufacturer says darkening of the cream itself is expected and does not change performance/safety; that statement must not be confused with treatment-associated blue-black skin darkening requiring discontinuation. Keep away from children and follow package integrity/expiry; no extra opened-tube shelf life is invented.